Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects

Journal of Opioid Management

Volumn 9, Issue 4, 2013, Pages 291-300

  Zannikos, Peter N ^a   Smit, Johan W ^b   Stahlberg, Hans Jürgen ^c   Wenge, Birger ^c   Hillewaert, Vera M ^b   Etropolski, Mila S ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

Extended release; Pharmacokinetics; Tapentadol

Indexed keywords

DRUG METABOLITE; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL; POLYETHYLENE; TAPENTADOL; TAPENTADOL O GLUCURONIDE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; EXTENDED RELEASE TABLET; FEMALE; FOOD INTAKE; HUMAN; JAPANESE; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NETHERLANDS; NORMAL HUMAN; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STEADY STATE; STUDY; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; EATING; FEMALE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NETHERLANDS; PHENOLS; TABLETS; THERAPEUTIC EQUIVALENCY; UNITED STATES; YOUNG ADULT;

EID: 84886659116     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2013.0171     Document Type: Article

References (24)

1. Tzschentke TM, Christoph T, Kögel B, et al.: (-)-(1R,2R)-3-(3- Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1): 265-276. (Pubitemid 47443277)
2. Tzschentke TM, De Vry J, Terlinden R, et al.: Tapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future. 2006; 31(12): 1053-1061.
3. Hartrick C, Van Hove I, Stegmann J-U, et al.: Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009; 31(2): 260-271.
4. Buynak R, Shapiro DY, Okamoto A, et al.: Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010; 11(11): 1787-1804.
5. Afilalo M, Etropolski MS, Kuperwasser B, et al.: Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010; 30(8): 489-505.
6. Etropolski M, Okamoto A, Shapiro DY, et al.: Dose conversion between tapentadol immediate and extended release for low back pain. Pain Physician. 2010; 13(1): 61-70.
7. Lange B, Kuperwasser B, Okamoto A, et al.: Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010; 27(6): 381-399.
8. Schwartz S, Etropolski M, Shapiro DY, et al.: Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011; 27(1): 151-162.
9. Wild JE, Grand S, Kuperwasser B, et al.: Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010; 10(5): 416-427.
10. Janssen Pharmaceuticals: Nucynta® ER (tapentadol) extended-release oral tablets C-II [package insert]. Raritan, NJ: Janssen Pharmaceuticals, Inc., 2011.
11. Grunenthal: Palexia® SR (tapentadol) prolonged-release oral tablets [summary of product characteristics]. Buckinghamshire, UK: Grunenthal Ltd., 2011.
12. Vosburg SK, Jones JD, Manubay JM, et al.: Assessment of the ease with which prescription opioid abusers prepare a TRF versus a non-TRF for abuse. Presented at: the 73rd Annual Scientific Meeting of The College on Problems of Drug Dependence (CPDD). Hollywood, FL. June 18-23, 2011: 189, Abstract 753.
13. Janssen: NUCYNTA® CR tapentadol controlled-release tablets [package insert]. Markham, Ontario, Canada: Janssen Inc., 2012.
14. The European Agency for the Evaluation of Medicinal Products (ed.): Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London: The European Agency for the Evaluation of Medicinal Products, 2001.
15. Minister of Public Works and Government Services: Guidance for Industry: Conduct and Analysis of Bioavailability and Bioequivalence Studies-Part B: Oral Modified Release Formulations. Canada: Minister of Public Works and Government Services, 1996.
16. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, et al. (eds.): Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Rockville, MD: Center for Drug Evaluation and Research, 2003.
17. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for industry: Food-effect bioavailability and fed bioequivalence studies. Available at http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833pdf. Accessed October 27, 2011.
18. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, et al. (eds.): Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: Center for Drug Evaluation and Research, 2001.
19. Smit JW, Oh C, Rengelshausen J, et al.: Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: Results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy. 2010; 30(1): 25-34.
20. Ortho-McNeil-Janssen Pharmaceuticals: Nucynta® (tapentadol) immediate-release oral tablets [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2011.
21. Kneip C, Terlinden R, Beier H, et al.: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008; 2(1): 67-75. (Pubitemid 351411265)
22. Terlinden R, Kögel BY, Englberger W, et al.: In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol. 2010; 32(1): 31-38.
23. Xu XS, Smit JW, Lin R, et al.: Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet. 2010; 49(10): 671-682.
24. Custodio JM, Wu CY, Benet LZ: Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008; 60(6): 717-733.